Nintedanib Heumann (Nintedanib)

The drug blocks several receptor tyrosine kinases—VEGFR, FGFR, and PDGFR—preventing signals that drive fibroblast growth, new blood‑vessel formation, and extracellular matrix deposition. By interrupting these pathways, Nintedanib reduces fibrotic tissue development in the lungs and can limit tumor angiogenesis in cancer therapy.

The specific dose and dosing schedule are determined by the prescribing physician based on the patient’s condition, weight, renal and hepatic function, and other clinical factors. Healthcare providers follow approved labeling and adjust the regimen as needed for safety and efficacy.

Safety data for Nintedanib in pregnancy and lactation are limited, and the product is not recommended for use unless the potential benefit justifies the potential risk to the fetus or infant. Women of child‑bearing potential should use effective contraception during treatment and for a period after discontinuation as advised by their clinician.

To place an order, visit the product page on gnhindia.com, submit an enquiry with the required quantity, and provide institutional or trade credentials. GNH India’s commercial team will verify eligibility, then respond with pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Nintedanib differs from pirfenidone, another antifibrotic, by targeting a broader range of tyrosine kinases involved in angiogenesis and fibroblast activity. Clinical studies suggest comparable efficacy in slowing lung‑function decline, but the side‑effect profiles vary; for example, nausea and diarrhea are more common with nintedanib, while photosensitivity is more typical with pirfenidone.

Store the product at room temperature, below 25 °C (77 °F). Keep the tablets in the original blister pack or container, protect them from moisture, excessive heat, and direct sunlight. Do not refrigerate or freeze the medication.

Nintedanib Heumann is taken orally, usually with food to reduce gastrointestinal discomfort. Patients should swallow the tablets whole with a full glass of water and follow the dosing schedule prescribed by their healthcare professional.

Serious risks include severe liver injury, significant bleeding events, arterial thromboembolism, gastrointestinal perforation, and marked hypertension. Patients should be monitored regularly for signs of liver dysfunction, bleeding, and blood‑pressure changes, and any concerning symptoms should be reported promptly to a healthcare provider.

Nintedanib is contraindicated in patients with known hypersensitivity to the active substance or any of its excipients. It should also be avoided in individuals with active bleeding disorders, uncontrolled hypertension, severe liver impairment, or those taking strong CYP3A4 inhibitors without appropriate dose adjustments.